Morgan Stanley has downgraded Halozyme Therapeutics to equal weight, a move that may seem counterintuitive given the bank simultaneously raised its price target to $109. The rationale: the company's royalty growth is likely to top out in 2029, making its current income stream less durable than many investors assume.
Halozyme, a biotechnology company, generates a significant portion of its revenue from royalties tied to Enhanze, a drug-delivery technology used in partnered medicines. Enhanze allows drugs to be administered via injection rather than intravenous infusion, and it's licensed to several large pharmaceutical partners. The technology has been a reliable cash generator, but Morgan Stanley's analysis suggests that contractual royalty-rate step-downs will kick in after 2029, capping the growth of this income stream.
That cap shifts the investment thesis toward what comes next. The bank points to several potential growth drivers, including Hypercon, a next-generation delivery approach, and antibody-drug conjugates (ADCs)—a class of cancer treatments that pair an antibody with a cell-killing payload. Halozyme also has another wave of Enhanze launches in the pipeline.
The challenge of unproven pipeline
The catch is that these early-stage programs carry significant uncertainty. Morgan Stanley uses "risk-adjusted" forecasts, which discount future revenue by the probability that a project actually succeeds. For Hypercon, the bank assigns a 15% chance of success, translating to roughly $146 million in risk-adjusted royalties by 2035—far below management's $1 billion target. The bank isn't modeling any royalties from the ADC opportunity or from Aerocon, another delivery technology.
This conservative approach highlights the gap between Halozyme's own projections and what Wall Street considers realistic. For investors, it means the stock's valuation may increasingly depend on pipeline milestones that are hard to predict and could take years to materialize.
Near-term business still healthy
Despite the downgrade, the near-term picture looks solid. Halozyme recently raised its 2026 revenue guidance to $1.86–$1.925 billion and lifted its non-GAAP earnings outlook. That helps explain why Morgan Stanley could raise its estimates while still tempering its rating—the existing business is performing well, but the long-term growth story is less certain.
For context, a similar dynamic played out with Henkel, where RBC lifted its price target but stayed neutral after a guidance raise, acknowledging strong near-term performance but limited upside. In Halozyme's case, the $109 target on a stock trading around $101 signals that the bank sees only modest upside over the next 12 months.
What it means for investors
The downgrade paired with a higher price target can be confusing, but it makes sense when you consider the math. A $109 target on a $101 stock implies a return of less than 8%, which may not justify a more bullish rating. More importantly, the 2029 royalty peak effectively shortens the "duration" of Enhanze-linked cash flows—meaning the value of those future payments is more sensitive to interest rates and less supportive of a high valuation today.
As a result, the stock's re-rating potential may be capped until clearer milestones emerge. Investors will likely watch for Hypercon to enter clinical trials or for an ADC program to show proof of concept. Until then, the market may treat Halozyme's pipeline with caution, similar to how Baird cut its Nvidia target while flagging uncertainties in that company's growth drivers.
For everyday investors, this story underscores the importance of looking beyond headline numbers. A company can raise guidance and still face headwinds if its long-term growth engine is less certain. When a bank downgrades a stock but raises its price target, it's often a signal that the easy gains are already priced in.
Halozyme's near-term business is healthy, but the market's focus is shifting to the pipeline. Whether those programs deliver will determine if the stock can break out of its current range. Until then, investors may want to keep an eye on the company's clinical milestones and any updates on its royalty contracts.
